Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Program Overview

This activity begins by providing guidance on identifying EGFR exon 20 insertion mutations in advanced non-small cell lung cancer (NSCLC) and information on their therapeutic relevance. New and emerging therapeutic options are discussed, with an emphasis on the most recently presented and/or published clinical data. Learners will also receive privileged insights into the optimal management of potential adverse effects.

Credit Expired
0.75 CE Credit(s)
Expires: October 26, 2022

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze the predictive/prognostic significance of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
  • Apply optimal diagnostic strategies for identifying NSCLC with EGFR exon 20 insertions
  • Assess clinical trial data regarding new and emerging treatment options for advanced NSCLC with EGFR exon 20 insertions
  • Employ appropriate techniques to manage adverse events associated with EGFR inhibition

Activity Faculty


Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO

Li Shu Fan Medical Foundation Professor, Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China


Shirish M. Gadgeel, MD

Chief, Division of Hematology and Oncology
Department of Internal Medicine
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, MI


Antonio Passaro, MD, PhD

Medical Oncologist, Division of Thoracic Oncology
European Institute of Oncology
Milan, Italy

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources